Follicular Lymphoma Chemo Free Precision Therapies

CE / CME

A Game Changer for Follicular Lymphoma: Mastering Use of Precision Therapies as Part of a Chemo-Free Treatment Paradigm

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: December 26, 2024

Expiration: June 25, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How confident are you in assessing patients for enrollment on clinical trials of BTK inhibitors and other novel therapies and combinations for R/R FL?

2.

Patient Case: 72-Yr-Old Woman With Relapsed FL



  • 72-yr-old woman with follicular lymphoma in need of treatment

  • She received R-CHOP for GCB-DLBCL 10 yr ago

  • 8 yr later, she relapsed with biopsy-confirmed, EZH2 wild-type indolent FL above and below the diaphragm

  • She received weekly rituximab x 4 cycles with little response, and subsequently transitioned to R2, which she took for 10 mo. She achieved a good PR but stopped R2 due to progressive fatigue

  • 8 mo after stopping R2, she has PD. In addition to diffuse adenopathy with a maximum diameter of 4.5 cm and SUVmax of 8, her LDH is slightly elevated, and her hemoglobin is slightly decreased at 10.8 g/dL

  • Fatigue improved after stopping R2, but it persists to some degree. She is the primary caregiver for her husband, who has early Alzheimer’s disease and dementia, and she’s anxious that he cannot cope without her around

Which of the following is the most accurate statement regarding this patient’s specific situation?

3.

Which of the following approved or emerging agents targets both CD19 and CD3?

4.

Patient Case: 45-Yr-Old Man With Multiply Relapsed FL



  • A 45-yr-old man was diagnosed with stage IV, symptomatic disease with splenomegaly and circulating disease

  • He was treated with R-CHOP for 6 cycles with an initial CR

    • He experienced early relapse within 9 mo of completing treatment



  • He then received obinutuzumab and lenalidomide with an initial partial response but experienced disease progression by Mo 8

  • Thereafter, he received axi-cel

  • On Day 4 of treatment, he develops a fever with stable vital signs

  • On Day 5, he develops hypotension that responds to IV fluid bolus followed by hypoxemia, requiring 3 L of nasal cannula oxygen

What is the next best treatment approach for this patient with grade 2 CRS?

5.

Patient Case: 73-Yr-Old Woman With FL



  • A 73-yr-old female with diabetes, labile HTN, and atrial fibrillation is diagnosed with stage III FL after presenting with palpable cervical lymphadenopathy, night sweats, and unintentional weight loss of 20 lb over 3 mo

  • Bendamustine and obinutuzumabstarted shortly after diagnosis

    • No maintenance obinutuzumab due to immunosuppression concerns during COVID pandemic; she tolerated treatment well and achieved a CR



  • However, ~1 yr after completing therapy, she developed symptoms, and was found to have biopsy-proven relapsed FL

  • Received second-line therapy with lenalidomide and rituximab (R2)

    • Tolerated well, but ultimately had to discontinue lenalidomide after 8 mo because of cytopenias

    • FL progressed within 4 mo, with reappearance of cervical lymph nodes and B symptoms



  • She now lives with her daughter who is unable to bring her to clinic regularly

In your current practice, what approved regimen would you recommend as the optimal next-line treatment for this woman with diabetes, HTN, atrial fibrillation, and transportation challenges?